Drug Trial Radar · NCT06179511
Study of AZD9829 in CD123+ Hematological Malignancies
Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Jan 31, 2024
Primary completion
Oct 31, 2025
Study completion Feb 24, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Dec 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a modular, multicentre, open-label, Phase I/II, dose-setting study. AZD9829 will be administered intravenously as monotherapy or in combination in participants with CD123 positive hematological malignancies.
Conditions
- Hematological Malignancies
Interventions
AZD9829Drug
AZD9829 will be administered by IV infusion
AZD9829Drug
AZD9829 will be administered by IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of dose limiting toxicities (DLTs).Time frame: Module 1 - 28 days.
- Safety evaluation of AZD9829: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0Time frame: Module 1 - From informed consent until 60 days after last dose of AZD9829.
- Identify RP2D in R/R AML patients.Time frame: Moldule 1 -From informed consent until 60 days after last dose of AZD9829.
Locations
22 sites in 10 countries. Site status is shown where the registry gives one.
Research Site
Duarte, California
Research Site
St Louis, Missouri
Research Site
New York, New York
Research Site
Chapel Hill, North Carolina
Research Site
Columbus, Ohio
Research Site
Houston, Texas
Research Site
Milwaukee, Wisconsin
Research Site
Heidelberg, Australia
Research Site
Melbourne, Australia
Research Site
Tianjin, China
Research Site
Frankfurt, Germany
Research Site
Bologna, Italy
Research Site
Kashiwa, Japan
Research Site
Osaka, Japan
Research Site
Yoshida-gun, Japan
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Barcelona, Spain
Research Site
Salamanca, Spain
Research Site
Tainan, Taiwan
Research Site
Taipei, Taiwan
Research Site
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.